I ntroduction: Information about continuous glucose monitoring (CGM) use in the UK is limited. We conducted an online survey of a representative sample of current CGM users in England, Scotland and Wales to address this deficit. Methods: The 29-item online survey was conducted between 29 December 2016 and 25 January 2017. Persons with type 1 diabetes (T1D) and caregivers of T1D children/ adolescents were recruited from mailing lists, using Nielsen and Harris Polling databases. Results: 315 patients and caregivers responded to the survey – 170 adult patients and 145 caregivers. Among respondents, 144 received full funding for CGM use, 72 received partial funding and 83 received no funding. Most reported improvements in glycated haemoglobin (HbA1c) (67.0%), fewer hypoglycaemia episodes (70.2%), improved hypoglycaemia awareness (77.5%) and better diabetes management (92.4%). Self-funders reported significantly higher CGM use (76.1%) than those who were fully funded (58.9%) and/or partially funded (65.9%), p=0.0008. Fewer than 50% of all respondents reported receiving guidance in interpreting CGM data from their diabetes care team; 30.1% of self-funders reported receiving no CGM support from their diabetes team compared with fully funded (2.8%) and partially funded (1.4%) respondents, p<0.0001. Conclusions: Patients with T1D and their caregivers are realising benefits from CGM use but are largely unsupported by the UK healthcare system.
Continuous glucose monitoring
(CGM), insulin, multiple daily insulin
injections (MDI), type 1 diabetes, selfmonitoring
of blood glucose (SMBG)
Christopher G Parkin has received consulting
fees from CeQur, Dexcom, Inc., Insulet, Mannkind, Roche
Diabetes Care and Senseonics. Melissa Holloway is Chief
Adviser of INPUT Patient Advocacy and has received
consulting fees from Dexcom, Inc. and Ascensia Diabetes
Care UK Limited. Jeffrey Truesdell and Tomas C Walker
are employees of Dexcom, Inc. Dexcom, Inc., provided
funding for the development of this manuscript.
Christopher G Parkin,
CGParkin Communications, Inc., Boulder
City, NV, US. E: firstname.lastname@example.org
The publication of this article was
supported by Dexcom, Inc. The views and opinions
expressed are those of the authors and do not
necessarily reflect those of Dexcom, Inc.
This article is published under the
Creative Commons Attribution Noncommercial License,
which permits any non-commercial use, distribution,
adaptation and reproduction provided the original
author(s) and source are given appropriate credit.
Share this Article
Related Content In Diabetes
The DFUC 2020 Dataset: Analysis Towards Diabetic Foot Ulcer Detection
touchREVIEWS in Endocrinology. 2021;17(1):5–11 DOI: https://doi.org/10.17925/EE.2021.17.1.5
Wounds on the feet, known as diabetic foot ulcers (DFUs), are a major complication of diabetes. DFUs can become infected, leading to amputation of the foot or lower limb. Patients who undergo amputation experience significantly reduced survival rates.1 In previous studies, researchers have achieved high accuracy in the recognition of DFUs using machine learning algorithms.2–5 […]
Diabetes Mellitus of Pituitary Origin: A Case Report
touchREVIEWS in Endocrinology. 2021;17(1):68–70 DOI: https://doi.org/10.17925/EE.2021.17.1.68
Acromegaly is a chronic, progressive disease characterized by an excess secretion of growth hormone, and consequently, increased circulating insulin-like growth factor 1 (IGF-1) levels. These patients typically exhibit acral and soft tissue overgrowth, headache, arthritis and visual disturbances. Impaired glucose tolerance and diabetes mellitus are also frequently associated with acromegaly.1 We describe a patient who […]
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
touchREVIEWS in Endocrinology. 2021;17(1):12-20 DOI: https://doi.org/10.17925/EE.2021.17.1.12
The prevalence of diabetes type 1 (T1D) and type 2 (T2D) is increasing worldwide; the number of people with diabetes was 463 million in 2019, but it is estimated to reach 700 million by 2045.1 The incidence of T1D is increasing in most countries.1 Age- and sex-standardized incidence rates from 1998 to 2013 (up to 25 years) […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!